Alpha-2-Heremans-Schmid glycoprotein (AHSG)

Alpha-2-Heremans-Schmid glycoprotein (AHSG), commonly known as fetuin-A, is a major plasma glycoprotein synthesized primarily by hepatocytes and secreted into the blood[1][4][8]. It consists of two polypeptide chains, derived from a single mRNA, and undergoes extensive posttranslational modifications, including glycosylation and phosphorylation[5][2]. Fetuin-A forms soluble complexes with calcium and phosphate, functioning as a key physiological inhibitor of ectopic (abnormal) calcification in soft tissues and blood vessels[1][4][2]. Elevated levels of AHSG/fetuin-A are linked to the development of insulin resistance, obesity, and metabolic syndrome, largely by enhancing pro-inflammatory signaling (e.g., TLR4 activation) and suppressing adiponectin production[1][6][4]. Fetuin-A is a recognized biomarker for risk stratification in diabetes, cardiovascular events, and liver disease, but is not a direct therapeutic target for existing drugs[4][1]. Both deficiency and overexpression of fetuin-A are implicated in human disease: deficiency can lead to soft-tissue calcification, while overexpression is associated with metabolic and inflammatory diseases[1][6][4].

Other names

Alpha-2-HS-glycoproteinFetuin-AAlpha-2-HS-glycoprotein chain AAlpha-2-HS-glycoprotein chain BFETUAA2HSHSGAAlpha-2-Z-globulinBa-alpha-2-glycoproteinPRO2743fetuin AAHSAPMR1

Not a therapeutic target; no approved drugs directly targeting AHSG. However, therapeutic modulation may impact calcification, insulin resistance, or inflammation.